Drug class
FMS-like tyrosine kinase 3 (FLT3) inhibitor; targeted antineoplastic kinase inhibitor
Mechanism of action
Inhibits FLT3 receptor tyrosine kinase signalling, including FLT3-ITD and FLT3-TKD mutations, reducing downstream proliferative signalling in FLT3-mutated leukaemic cells. It also inhibits additional kinases at clinically relevant concentrations.
General use cases
- Treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation detected by an FDA-approved test; specialist haematology use
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
